Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Antoine Italiano

Showing results (311-320 of 418) with videos related to

Pageof 42
Sort By:
European Journal of Cancer (Oxford, England : 1990)|October 19, 2013
Primary cardiac sarcomas: a retrospective study of the French Sarcoma GroupNicolas Isambert, Isabelle Ray-Coquard, Antoine Italiano, et al.
Cancer Research Communications|September 3, 2025
IPH5201, an anti-CD39 monoclonal antibody, as monotherapy or in combination with durvalumab in advanced solid tumorsJohn Powderly, Martina Imbimbo, Antoine Italiano, et al.
The Lancet. Oncology|April 14, 2018
Tazemetostat, an EZH2 inhibitor, in relapsed or refractory B-cell non-Hodgkin lymphoma and advanced solid tumours: a first-in-human, open-label, phase 1 studyAntoine Italiano, Jean-Charles Soria, Maud Toulmonde, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 29, 2015
Paclitaxel Given Once Per Week With or Without Bevacizumab in Patients With Advanced Angiosarcoma: A Randomized Phase II TrialIsabelle L Ray-Coquard, Julien Domont, Emmanuelle Tresch-Bruneel, et al.
Eclinicalmedicine|May 31, 2019
Trabectedin and RAdiotherapy in Soft Tissue Sarcoma (TRASTS): Results of a Phase I Study in Myxoid Liposarcoma from Spanish (GEIS), Italian (ISG), French (FSG) Sarcoma GroupsAlessandro Gronchi, Nadia Hindi, Josefina Cruz, et al.
European Journal of Cancer (Oxford, England : 1990)|April 25, 2021
Efficacy and safety of regorafenib in patients with metastatic or locally advanced chondrosarcoma: Results of a non-comparative, randomised, double-blind, placebo controlled, multicentre phase II studyFlorence Duffaud, Antoine Italiano, Emannuelle Bompas, et al.
Cancer Treatment and Research Communications|July 30, 2021
Safety, pharmacokinetics, and efficacy of budigalimab with rovalpituzumab tesirine in patients with small cell lung cancerEmiliano Calvo, Alexander Spira, María de Miguel, et al.
The Lancet. Oncology|February 21, 2020
Cabozantinib in patients with advanced Ewing sarcoma or osteosarcoma (CABONE): a multicentre, single-arm, phase 2 trialAntoine Italiano, Olivier Mir, Simone Mathoulin-Pelissier, et al.
Cell Reports. Medicine|November 26, 2024
Analysis of PD1, LAG3, TIGIT, and TIM3 expression in human lung adenocarcinoma reveals a 25-gene signature predicting immunotherapy responseJean-Philippe Guégan, Florent Peyraud, Bérengère Dadone-Montaudie, et al.
European Journal of Cancer (Oxford, England : 1990)|February 4, 2025
Diagnosis and treatment of dermatofibrosarcoma protuberans. European interdisciplinary guideline - update 2024Philippe Saiag, Celeste Lebbe, Lieve Brochez, et al.
Pageof 42

Showing results (311-320 of 418) with videos related to

Sort By:
Pageof 42
European Journal of Cancer (Oxford, England : 1990)|October 19, 2013
Primary cardiac sarcomas: a retrospective study of the French Sarcoma GroupNicolas Isambert, Isabelle Ray-Coquard, Antoine Italiano, et al.
Cancer Research Communications|September 3, 2025
IPH5201, an anti-CD39 monoclonal antibody, as monotherapy or in combination with durvalumab in advanced solid tumorsJohn Powderly, Martina Imbimbo, Antoine Italiano, et al.
The Lancet. Oncology|April 14, 2018
Tazemetostat, an EZH2 inhibitor, in relapsed or refractory B-cell non-Hodgkin lymphoma and advanced solid tumours: a first-in-human, open-label, phase 1 studyAntoine Italiano, Jean-Charles Soria, Maud Toulmonde, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 29, 2015
Paclitaxel Given Once Per Week With or Without Bevacizumab in Patients With Advanced Angiosarcoma: A Randomized Phase II TrialIsabelle L Ray-Coquard, Julien Domont, Emmanuelle Tresch-Bruneel, et al.
Eclinicalmedicine|May 31, 2019
Trabectedin and RAdiotherapy in Soft Tissue Sarcoma (TRASTS): Results of a Phase I Study in Myxoid Liposarcoma from Spanish (GEIS), Italian (ISG), French (FSG) Sarcoma GroupsAlessandro Gronchi, Nadia Hindi, Josefina Cruz, et al.
European Journal of Cancer (Oxford, England : 1990)|April 25, 2021
Efficacy and safety of regorafenib in patients with metastatic or locally advanced chondrosarcoma: Results of a non-comparative, randomised, double-blind, placebo controlled, multicentre phase II studyFlorence Duffaud, Antoine Italiano, Emannuelle Bompas, et al.
Cancer Treatment and Research Communications|July 30, 2021
Safety, pharmacokinetics, and efficacy of budigalimab with rovalpituzumab tesirine in patients with small cell lung cancerEmiliano Calvo, Alexander Spira, María de Miguel, et al.
The Lancet. Oncology|February 21, 2020
Cabozantinib in patients with advanced Ewing sarcoma or osteosarcoma (CABONE): a multicentre, single-arm, phase 2 trialAntoine Italiano, Olivier Mir, Simone Mathoulin-Pelissier, et al.
Cell Reports. Medicine|November 26, 2024
Analysis of PD1, LAG3, TIGIT, and TIM3 expression in human lung adenocarcinoma reveals a 25-gene signature predicting immunotherapy responseJean-Philippe Guégan, Florent Peyraud, Bérengère Dadone-Montaudie, et al.
European Journal of Cancer (Oxford, England : 1990)|February 4, 2025
Diagnosis and treatment of dermatofibrosarcoma protuberans. European interdisciplinary guideline - update 2024Philippe Saiag, Celeste Lebbe, Lieve Brochez, et al.
Pageof 42